Market Intelligence

Access the latest earnings reports, market analysis, hot topics, and individual stock insights

Report Categories

View All

Recent Articles

View All
BRCC BRC posts 17 percent YoY Q4 2025 revenue growth shares dip slightly on negative per share earnings Is Century Comm CCS stock testing support Q4 2025 Earnings Fall Short Nuveen JPC Stock Downgrade Alert Touches High 20260420 Chevron Corporation CVX Top Zacks Rank 1 Strong Buy Amid Resilient Energy Earnings Trends LOOP Loop Industries posts 7017 percent Q1 2026 revenue growth shares fall 338 percent despite narrow EPS beat What Guggenheim GUG does that makes it resilient Bearish Sentiment 20260508 KALU Kaiser reports far higher than expected Q1 2026 EPS but shares edge down 121 percent in todays trading Why Deere DE is trading below its true worth Slight Rise 20260506 How SIMPPLE LTD SPPL is investing for future growth Quince Therapeutics QNCX Q4 2025 Results Miss Estimates EPS 710 vs 193 IDEA Group AMTD Q4 2020 Earnings EPS 122 Beats Estimates Colgate CL Stock Jumps 203 Approaching 9442 20260518 Twenty One XXI Declines 667 Amid Market Weakness 20260515 Currenc CURR Delivers Q3 2025 Beat EPS 005 vs 012 Expected OpenAI Reportedly Files for IPO Targeting September Listing with 1 Trillion Valuation Shoals SHLS Reports Strong Q1 2026 Revenue NA EPS Beats Government Pledges 120 Million to Support UK Ceramics Industry Incannex Healthcare IXHL Q1 2026 Earnings Deepening Losses as ClinicalStage Biotech Continues PreRevenue Development SCNX Q1 2026 Earnings Strong EPS Beat Driven by Cost Management Illinois Tool Works ITW Q1 2026 Earnings EPS Beats Estimates as Operational Strength Drives Modest Share Gain IDYA Q1 2026 Earnings PreRevenue Biotech Misses EPS Estimates as RD Pipeline Progresses Dynatrace DT Q1 2026 Earnings Software Firm Beats EPS Expectations Shares Gain 53 Community Health Systems CYH Edges Higher Navigating Resistance Levels Amid Sector Volatility Lifevantage LFVN Surges 45 on Rising Volume Testing Key Resistance at 589 OYSE Hovers Near Trust Value as Slight Dip Reflects Cautious Trading Allogene Therapeutics ALLO Surges 755 as Biotech Momentum Builds